Über ein neues Ultrakurznarkotikum

Weese, H.; Koss, F. H.

doi:10.1055/s-0028-1115490

Cited by 26 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…or 17.85 mg./kg.). These figures agree closely with others that have been published (Orkin et al, 1958;Henderson and Mackett, 1958 D that its properties made it highly suitable for out-patient anaesthesia (Weese and Koss, 1954;Nobes, 1955aNobes, , 1955bRuddell, 1955;McColl, 1955;Young, 1956;Henderson and Mackett, 1957). On the other hand, its brevity of action (compared with thiopentone) has been disputed by some workers, who have also reported unfavourable side-effects and sequelae (O'Mullane, 1957: Simmons andBlanshard, 1957;Henderson and Mackett, 1958).…”

Section: Methodssupporting

confidence: 79%

See 1 more Smart Citation

Recovery From Buthalitone Anaesthesia

Simmons

Curwen

1961

Survey of Anesthesiology

View full text Add to dashboard Cite

Section: Methodssupporting

confidence: 79%

“…Buthalitone sodium has been claimed to possess this property as well as various other advantages over existing agents (Weese and Koss, 1954;Nobes, 1955aNobes, , 1955bRuddell, 1955). The present investigation was designed to compare buthalitone sodium with thiopentone sodium, using a new technique to measure the rate of recovery.…”

Section: Discussionmentioning

confidence: 99%

Recovery From Buthalitone Anaesthesia

Simmons

Curwen

1961

Survey of Anesthesiology

View full text Add to dashboard Cite

“…Little work appears to have been done upon the electrocardiographic changes produced by buthalitone in man, but Weese and Koss (1954) report that no irregularities were observed in their experiments with dogs. Our technique for making the recordings was as follows.…”

Section: Electrocardiographs Changesmentioning

confidence: 99%

The Comparative Potencies of Buthalitone and Thiopentone in Out-Patient Anaesthesia

Henderson

Mackett

1958

British Journal of Anaesthesia

View full text Add to dashboard Cite

THIOPENTONE was introduced to clinical anaesthesia by Lundy in 1934 and the first reports of its use appeared in the following year (Lundy, 1935; Lundy and Tovell, 1935). Since then, thiopentone has almost entirely superseded other intravenous agents and has become the standard agent for inducing anaesthesia. It is not, however, without certain dangers. The main disadvantages are the occasional occurrence of laryngeal spasm (Lee, 1953; Dundee, 1956) and the ease with which respiratory depression due to overdosage can be produced. Another objection to thiopentone is that, following induction and a brief period of anaesthesia, the patients often have a relatively prolonged period when they are drowsy and confused and in a state described by Lundy (1935) as resembling alcoholic inebriation. Research workers have been constantly seeking other similar drugs which.would show a shorter recovery period with less postanaesthetic confusion, and buthalitone was introduced as such a drug. Claims have also been made that the incidence of respiratory depression and vagotonic effects is less with this drug than with thiopentone (Davidson and Love, 1956). Buthalitone was first prepared by Miller et al. (1936) but it was not used clinically until 1954 when Weese and Koss reported on a clinical trial of 350 cases. This has been followed by numerous reports of other clinical trials in which this drug has been used (

show abstract

“…It was introduced as an anaesthetic by Weese and Koss (1954) and has achieved its greatest popularity on the European continent. after intravenous administration of buthalitone or thiopentone, plasma concentrations in young human subjects have been followed.…”

mentioning

confidence: 99%

“…It was introduced as an anaesthetic by Weese and Koss (1954) and has achieved its greatest popularity on the European continent. It was introduced as an anaesthetic by Weese and Koss (1954) and has achieved its greatest popularity on the European continent.…”

mentioning

confidence: 99%

Thiopentone and Buthalitone the Relationship Between Depth of Anaesthesia, Plasma Concentration and Plasma Protein Binding

Kane

Smith

1960

Survey of Anesthesiology

View full text Add to dashboard Cite

For 24 hr. after intravenous administration of buthalitone or thiopentone, plasma concentrations in young human subjects have been followed. Buthalitone was distributed to the tissues more rapidly but was metabolized at a slower rate than thiopentone. The relationships between these findings and differences in plasma protein binding and oil/water partition coefficients were studied. It is suggested that some of the differences observed in potency between the substances is a reflection of differences in their modes of distribution. No relationship was found between speed of recovery from anaestbesia and plasma barbiturate concentrations. Of the new ultra-short-acting thiobarbiturates, the most commonly employed is buthalitone sodium, the sodium salt of 5-allyl-5-isobutyl-thiobarbituric acid. It was introduced as an anaesthetic by Weese and Koss (1954) and has achieved its greatest popularity on the European continent. In Britain some authors regard it as useful for anaesthesia of brief duration (Young, 1956; Henderson and Mackett, 1957), while others conclude that it offers no advantage over thiopentone sodium, the sodium salt of 5-ethyl-5-(l-methylbutyl)-thiobarbituric acid (Simmons and Blanshard, 1957; O'Mullane, 1957). It is generally agreed that buthalitone appears to be a less potent anaesthetic than thiopentone when given in the same dose. The present investigation had three main objects: first, to compare the rates of elimination of the two substances from the blood stream after intravenous injection and thereby to deduce, if possible, any difference there might be in the rates of metabolism of the two; second, to attempt to relate changes in plasma concentrations with the clinical signs of recovery from anaesthesia; and third, to compare two physical attributes, the plasma protein binding and the oil/water partition coefficients, in an attempt to account for the differences in clinical activity of the two drugs. METHODS Clinical.-The patients were otherwise healthy male subjects, aged 18 to 37 years, weighing 58.5 to 86.2 kg., who underwent minor operative procedures such as incisions, manipulations, and excisions of cysts. Premedication consisted solely of atropine sulphate (0.6 mg. given subcutaneously) 45 min. before operation. Doses both of buthalitone (16 patients) and of thiopentone (10 patients), based on 11 mg./ kg. body weight, were administered as 10 and 5% (w/v) solutions respectively at a rate of 1 ml. /sec. The drug was injected into a vein in the antecubital fossa, and blood samples were withdrawn from a vein in the opposite arm at-1, 2, 4, 8, 16, 32 min., and 1, 2, 4, 8, and 24 hr. from the mean time of the injection. In most cases some supplementary anaesthesia was required, and nitrous oxide, oxygen, and trichlorethylene or cyclopropane and oxygen were administered. In a few cases muscle relaxants, with or without controlled respiration, were needed. Three patients were given a second dose of buthalitone 16 min. after the first. Three tests were applied to six subjects who received buthal...

show abstract

Über ein neues Ultrakurznarkotikum

Cited by 26 publications

References 0 publications

Recovery From Buthalitone Anaesthesia

Recovery From Buthalitone Anaesthesia

The Comparative Potencies of Buthalitone and Thiopentone in Out-Patient Anaesthesia

Thiopentone and Buthalitone the Relationship Between Depth of Anaesthesia, Plasma Concentration and Plasma Protein Binding

Contact Info

Product

Resources

About